Prognostic factors of recurrent intrahepatic cholangiocarcinoma after hepatectomy: A retrospective study

Table 1 Univariate analysis of prognostic factors after intrahepatic cholangiocarcinoma recurrence following hepatectomy

Factors	Cases, n (%)	Median survival after recurrence, mo (95%CI)	P value1
Sex			0.123
Male	34 (63.0)	4.0 (1.2-6.8)
Female	20 (37.0)	3.0 (1.1-4.9)
Age (yr)			0.031
< 65	42 (77.8)	4.0 (2.3-5.8)
≥ 65	12 (22.2)	3.0 (1.3-5.1)
Smoking			0.059
No	20 (37.0)	5.0 (2.0-8.0)
Yes	34 (63.0)	3.0 (1.0-4.1)
Alcohol consumption			0.004
No	10 (18.5)	10.0 (3.0-17.0)
Yes	44 (81.5)	3.0 (1.9-4.2)
Hypertension			0.309
No	38 (70.4)	4.0 (2.4-5.6)
Yes	16 (29.6)	4.0 (0.0-11.3)
Diabetes			0.193
No	45 (83.3)	4.0 (2.5-5.5)
Yes	9 (16.7)	8.0 (1.0-15.0)
Hepatitis B			0.904
Negative	30 (55.6)	3.0 (1.3-4.7)
Positive	24 (44.4)	5.0 (2.0-8.0)
Hepatitis C			0.175
Negative	45 (83.3)	4 .0 (2.2-5.8)
Positive	9 (16.7)	5.0 (2.1-7.9)
Anti-hepatitis-virus			0.969
No	29 (53.7)	4.0 (2.4-5.6)
Yes	25 (46.3)	5.0 (1.9-8.1)
Cholelithiasis			0.181
No	44 (81.5)	4.0 (2.1-5.9)
Yes	10 (18.5)	2.0 (0.0-4.8)
CA19-9 (U/mL) (initial)			0.002
< 200	33 (61.1)	5.0 (1.8-8.2)
≥ 200	21 (38.9)	2.0 (1.3-2.7)
CEA (ng/mL) (initial)			0.356
< 5	34 (63.0)	4.0 (2.1-5.9)
≥ 5	20 (37.0)	3.0 (0.8-5.2)
Hepatectomy			0.855
Limited	38 (70.4)	4.0 (2.1-5.9)
Extended	16 (29.6)	3 .0 (0.0-6.9)
Lymph node dissection			0.909
No	35 (64.8)	4.0 (2.2-5.8)
Yes	19 (35.2)	5.0 (2.1-7.9)
Adjuvant treatment			0.619
No	34 (63.0)	3 .0 (0.1-5.9)
Yes	20 (37.0)	4 .0 (2.7-5.3)
Tumor size (cm)			0.884
< 5	14 (25.9)	4.0 (0.4-7.6)
≥ 5	40 (74.1)	4 .0 (2.0-6.0)
Multiplicity			0.803
Solitary	46 (85.2)	4.0 (1.4-6.6)
Multiple	8 (14.8)	3.0 (1.3-4.7)
Satellite nodules			0.953
No	34 (63.0)	4.0 (2.1-5.9)
Yes	20 (37.0)	4.0 (2.4-5.6)
Histological grade			0.021
PD	22 (40.7)	2.0 (1.2-2.8)
WD or MD	32 (59.3)	5.0 (3.5-6.5)
Vascular invasion			0.705
No	49 (90.7)	4.0 (2.1-5.9)
Yes	5 (9.3)	5.0 (1.7-8.3)
Lymph node metastasis			0.531
No	29 (53.7)	3.0 (0.9-5.1)
Yes	25 (46.3)	5.0 (2.6-7.4)
Perineural invasion			0.428
No	45 (83.3)	4.0 (2.5-5.5)
Yes	9 (16.7)	2.0 (1.3-2.7)
Biliary invasion			0.003
No	35 (64.8)	5.0 (2.6-7.4)
Yes	19 (35.2)	2.0 (1.2-2.8)
Vascular tumour thrombi			0.002
No	42 (77.8)	5.0 (3.2-6.8)
Yes	12 (22.2)	2.0 (1.2-2.6)
AJCC T category			0.196
T1–2	14 (25.9)	4.0 (0.0-11.3)
T3–4	40 (74.1)	4.0 (2.1-5.9)
DFS			0.003
< 6 mo	27 (50.0)	2.0 (0.7-3.3)
≥ 6 mo	27 (50.0)	6.0 (2.3-9.7)
CA19-9 (U/mL) (recurrence)			0.002
< 200	35 (64.8)	4.0 (1.3-6.7)
≥ 200	19 (35.2)	2.0 (1.2-2.8)
CEA (ng/mL) (recurrence)			0.378
< 5	41 (75.9)	4.0 (2.3-5.7)
≥ 5	13 (24.1)	7.0 (1.7-12.3)
NLR (recurrence)			0.804
< 2	24 (44.4)	5.0 (2.8-7.2)
≥ 2	30 (55.6)	2.0 (0.9-3.1)
Recurrent site			0.334
Intrahepatic	24 (44.4)	4.0 (2.3-5.7)
Extrahepatic	6 (11.2)	3.0 (0.0-11.6)
Intrahepatic + extrahepatic	24 (44.4)	2.0 (0.4-3.6)
Treatment after recurrence			< 0.001
No	12 (22.2)	2.0 (1.0-2.8)
Yes	42 (77.8)	5.0 (2.9-7.1)

¹Data are based on log-rank test.

N: Number; CI: Confidence interval; CA19-9: Serum carbohydrate antigen 19-9; CEA: Carcinoembryonic antigen; PD: Poor-differentiated; WD: Well-differentiated; MD: Moderate differentiated; NLR: Neutrophil-to-lymphocyte ratio; AJCC: the American Joint Committee on Cancer; DFS: Disease free survival.